The estimated Net Worth of Michael Goldberg is at least $10.2 Milione dollars as of 11 April 2022. Mr. Goldberg owns over 500 units of Caredx Inc stock worth over $1,790,743 and over the last 17 years he sold CDNA stock worth over $8,085,577. In addition, he makes $323,217 as Lead Independent Director at Caredx Inc.
Michael has made over 20 trades of the Caredx Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 500 units of CDNA stock worth $610 on 11 April 2022.
The largest trade he's ever made was exercising 64,525 units of Caredx Inc stock on 10 May 2021 worth over $190,349. On average, Michael trades about 2,939 units every 35 days since 2007. As of 11 April 2022 he still owns at least 62,767 units of Caredx Inc stock.
You can see the complete history of Mr. Goldberg stock trades at the bottom of the page.
Michael D. Goldberg serves as Lead Independent Director of the Company. Mr. Goldberg has served as a director and chairman of the Board of Directors of DNAnexus, Inc., a cloud-based genome informatics and data management company, and as an advisor to other private life science companies since May 2011. Mr. Goldberg has also served on the Board of Directors for eHealth, Inc. since 1999. From January 2005 to May 2011, Mr. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine and digital healthcare. In 1987, Mr. Goldberg founded Axion, Inc., a cancer treatment services company, and served as its Chief Executive Officer until its sale in 1995. Prior to Axion, Mr. Goldberg was a partner at the venture capital firm of Sevin Rosen Management Company from 1985 to 1987, where he established the firm’s life science practice, and director of corporate development at Cetus Corporation from 1981 to 1985. Mr. Goldberg has served as a member of the Board of Directors of numerous companies in the biotech and health sciences industry. Mr. Goldberg has served on boards and advisory boards of a number of industry, academic and public policy institutions in biotechnology and finance, including the Board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute for Regenerative Medicine, the Board of the Western Association of Venture Capitalists, the Advisory Boards for the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, the UCSF Center for Translational and Policy Research on Personalized Medicine and the Stanford Distinguished Careers Institute. Mr. Goldberg holds a B.A. from Brandeis University and an M.B.A. from the Stanford Graduate School of Business.
As the Lead Independent Director of Caredx Inc, the total compensation of Michael Goldberg at Caredx Inc is $323,217. There are 8 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of $8,855,740.
Michael Goldberg is 62, he's been the Lead Independent Director of Caredx Inc since 2020. There are 3 older and 12 younger executives at Caredx Inc. The oldest executive at Caredx Inc is Ralph Snyderman, 80, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O CAREDX, INC., 8000 MARINA BOULEVARD, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon e Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: